Accordingly, targeting TAMs via the CSF1/CSF1R or CX3CL1/CX3CR1 signaling pathway is an attractive therapy for cancers associated with increased numbers of TAMs (reviewed in refs.46,47). Here, CX3CR1 is linked to cancer.